SCHEMBL6916539

SCHEMBL6916539

CS(=O)(=O)c1ccc(CN2C(=O)NC3SC=C(C#CCc4cccnc4)N3C2=O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.37
PTGS1 P23219 1/20 0.37
MDM2 Q00987 1/20 0.35
NAMPT P43490 1/20 0.34
BRD4 O60885 1/20 0.33
PKM P14618 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CCR9 P51686 1/20 0.33
JAK2 O60674 1/20 0.33
PTK2 Q05397 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
LMNA P02545 1/20 0.32
TLR7 Q9NYK1 2/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914379 0.89 CYP3A4 (0.37) NAMPTBRD4CYP3A4CYP2C9PPARG
SCHEMBL6472061 0.69 TLR7 (0.41) PTGS2PTGS1PKMCYP3A4CYP2C9
SCHEMBL6485796 0.68 PTGS2 (0.39) PTGS2PTGS1NAMPTBRD4PKM
SCHEMBL6230930 0.68 DHPS (0.39) PTGS2PTGS1NAMPTPKMJAK2
SCHEMBL6472066 0.67 PTGS2 (0.36) PTGS2PTGS1NAMPTCYP3A4CYP2C9
SCHEMBL6231683 0.65 PTGS2 (0.37) PTGS2PTGS1NAMPTCYP3A4CYP2C9
SCHEMBL6296203 0.64 MMP13 (0.51) PTGS2PTGS1LMNA
SCHEMBL6298053 0.64 MMP13 (0.67) LMNA
SCHEMBL6745747 0.63 MDM2 (0.37) PTGS2PTGS1MDM2NAMPTCYP3A4
SCHEMBL6745719 0.61 MDM2 (0.36) PTGS2PTGS1MDM2NAMPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019054-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019054-A1 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib MMP13, MMP11, MMP10 PTGS2 53/4885PTGS1 98/4885MDM2 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.